Improving Biomarkers in Atopic Dermatitis: Insights from Lebrikizumab Studies

In recent findings from the ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) studies, lebrikizumab has shown promising results in treating moderate-to-severe atopic dermatitis (AD), according to a poster presented at the Revolutionizing Atopic Dermatitis (RAD) June 2024 meeting. Researchers have conducted a detailed analysis aiming to establish correlations between clinical improvements in AD and reductions in specific serum biomarkers relevant to the condition.

The study, which involved serum samples from 108 patients receiving either lebrikizumab or placebo, examined a range of biomarkers including IL-13, CCL2, CCL4, CCL11, CCL13, CCL17 (TARC), CCL22, CCL26 (eotaxin-3), CXCL10, total IgE, IL-4, IL-5, and periostin. Key clinical measures assessed included the Investigator’s Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Pruritus Numeric Rating Scale (NRS).

At baseline, significant positive correlations were observed between EASI scores and biomarkers such as IL-13, periostin, IL-5, IgE, CCL13, CCL17, CCL22, and CCL26 (p<0.05). Throughout the treatment period (baseline, week 4, week 16, and week 52), improvements in clinical measures (EASI, IGA, and Pruritus NRS) consistently correlated with reductions in periostin, CCL13, CCL17, CCL22, and CCL26 (p<0.05). Additionally, improvement in IGA scores was associated with decreased levels of IgE (p<0.05).

" Clinical measures of improvement in the signs and symptoms of AD are correlated with reductions in AD biomarkers in patients treated with lebrikizumab,” concluded the study authors.

Reference:

Guttman-Yassky E, Okragly A, Sun Z, Nickoloff BJ, et al. Clinical measures of improvement in atopic dermatitis are correlated with reductions in relevant biomarkers in patients treated with lebrikizumab. Poster presented at: Revolutionizing Atopic Dermatitis; June 8-10, 2024; Chicago, IL.